Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling

Wang,Luqi; Wang,Yue; Chen,Andy; Jalali,Aydin; Liu,Shengzhi; Guo,Yunxia; Na,Sungsoo; Nakshatri,Harikrishna; Li,Bai-Yan; Yokota,Hiroki

doi:10.3892/ijo.2018.4481

Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling

Authors:
- Luqi Wang
- Yue Wang
- Andy Chen
- Aydin Jalali
- Shengzhi Liu
- Yunxia Guo
- Sungsoo Na
- Harikrishna Nakshatri
- Bai-Yan Li
- Hiroki Yokota
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, Indianapolis, IN 46202, USA, Department of Surgery, Simon Cancer Research Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Published online on: July 13, 2018 https://doi.org/10.3892/ijo.2018.4481
Pages: 1001-1012
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy for suppressing tumor growth and metastasis tends to induce various effects on other organs. Using AZD7762, an inhibitor of checkpoint kinase (Chk) 1 and 2, the present study examined its effect on mammary tumor cells in addition to bone cells (osteoclasts, osteoblasts and osteocytes), using monolayer cell cultures and three-dimensional (3D) cell spheroids. The results revealed that AZD7762 blocked the proliferation of 4T1.2 mammary tumor cells and suppressed the development of RAW264.7 pre-osteoclast cells by downregulating nuclear factor of activated T cells cytoplasmic 1. AZD7762 also promoted the mineralization of MC3T3 osteoblast-like cells and 3D bio-printed bone constructs of MLO-A5 osteocyte spheroids. While a Chk1 inhibitor, PD407824, suppressed the proliferation of tumor cells and the differentiation of pre-osteoclasts, its effect on gene expression in osteoblasts was markedly different compared with AZD7762. Western blotting indicated that the stimulating effect of AZD7762 on osteoblast development was associated with the inhibition of Chk2 and the downregulation of cellular tumor antigen p53. The results of the present study indicated that in addition to acting as a tumor suppressor, AZD7762 may prevent bone loss by inhibiting osteoclastogenesis and stimulating osteoblast mineralization.

View Figures

View References

1	Smits VA and Gillespie DA: DNA damage control: Regulation and functions of checkpoint kinase 1. FEBS J. 282:3681–3692. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ: Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science. 277:1497–1501. 1997. View Article : Google Scholar : PubMed/NCBI
3	Narayanaswamy PB, Tkachuk S, Haller H, Dumler I and Kiyan Y: CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling. Cell Death Dis. 7:e23832016. View Article : Google Scholar : PubMed/NCBI
4	McNeely S, Beckmann R and Bence Lin AK: CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther. 142:1–10. 2014. View Article : Google Scholar
5	Kuo C-Y, Zupkó I, Chang F-R, Hunyadi A, Wu C-C, Weng T-S and Wang H-C: Dietary flavonoid derivatives enhance chemotherapeutic effect by inhibiting the DNA damage response pathway. Toxicol Appl Pharmacol. 311:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
6	Massey AJ, Stokes S, Browne H, Foloppe N, Fiumana A, Scrace S, Fallowfield M, Bedford S, Webb P, Baker L, et al: Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget. 6:35797–35812. 2015. View Article : Google Scholar : PubMed/NCBI
7	Origanti S, Cai SR, Munir AZ, White LS and Piwnica-Worms H: Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene. 32:577–588. 2013. View Article : Google Scholar
8	Gokulnath M, Swetha R, Thejaswini G, Shilpa P and Selvamurugan N: Transforming growth factor-β1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metal-loproteinase-13 gene in human breast cancer cells. Int J Biol Macromol. 94:370–377. 2017. View Article : Google Scholar
9	Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 7:2955–2966. 2008. View Article : Google Scholar : PubMed/NCBI
10	Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, et al: Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med. 7:432009. View Article : Google Scholar : PubMed/NCBI
11	Liu S, Liu Y, Minami K, Chen A, Wan Q, Yin Y, Gan L, Xu A, Matsuura N, Koizumi M, et al: Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model. Oncotarget. 9:9364–9378. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zannini L, Delia D and Buscemi G: CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 6:442–457. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wu X, Webster SR and Chen J: Characterization of tumor-associated Chk2 mutations. J Biol Chem. 276:2971–2974. 2001. View Article : Google Scholar
14	Hamamura K, Minami K, Tanjung N, Wan Q, Koizumi M, Matsuura N, Na S and Yokota H: Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling. Int J Oncol. 44:1980–1988. 2014. View Article : Google Scholar : PubMed/NCBI
15	Hamamura K, Tanjung N and Yokota H: Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab. 31:618–628. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu Z, Lv Y, Zhao N, Guan G and Wang J: Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate. Cell Death Dis. 6:e18222015. View Article : Google Scholar : PubMed/NCBI
17	Raschke WC, Baird S, Ralph P and Nakoinz I: Functional macrophage cell lines transformed by Abelson leukemia virus. Cell. 15:261–267. 1978. View Article : Google Scholar : PubMed/NCBI
18	Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH and Franceschi RT: Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 14:893–903. 1999. View Article : Google Scholar : PubMed/NCBI
19	Kato Y, Boskey A, Spevak L, Dallas M, Hori M and Bonewald LF: Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res. 16:1622–1633. 2001. View Article : Google Scholar : PubMed/NCBI
20	Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, et al: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 17:163–170. 1999. View Article : Google Scholar : PubMed/NCBI
21	Chen A, Wang L, Li B-Y, Sherman J, Ryu JE, Hamamura K, Liu Y, Nakshatri H and Yokota H: Reduction in migratory phenotype in a metastasized breast cancer cell line via down-regulation of S100A4 and GRM3. Sci Rep. 7:34592017. View Article : Google Scholar
22	Moldovan NI, Hibino N and Nakayama K: Principles of the Kenzan method for robotic cell spheroid-based three-dimensional bioprinting. Tissue Eng Part B Rev. 23:237–244. 2017. View Article : Google Scholar
23	Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
24	Wang X, Kua H-Y, Hu Y, Guo K, Zeng Q, Wu Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, et al: p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol. 172:115–125. 2006. View Article : Google Scholar
25	Cailleau R, Young R, Olivé M and Reeves WJ Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 53:661–674. 1974. View Article : Google Scholar : PubMed/NCBI
26	Soule HD, Vazguez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 51:1409–1416. 1973. View Article : Google Scholar : PubMed/NCBI
27	Yokota H, Hamamura K, Chen A, Dodge TR, Tanjung N, Abedinpoor A and Zhang P: Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells. BMC Musculoskelet Disord. 14:1972013. View Article : Google Scholar : PubMed/NCBI
28	National Research Council (US) Committee: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press; Washington, DC: 2011
29	Ascione F, Vasaturo A, Caserta S, D'Esposito V, Formisano P and Guido S: Comparison between fibroblast wound healing and cell random migration assays in vitro. Exp Cell Res. 347:123–132. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Zhu L and Peng B: Effect of BioAggregate on osteoclast differentiation and inflammatory bone resorption in vivo. Int Endod J. 48:1077–1085. 2015. View Article : Google Scholar
31	Miyazaki T, Miyauchi S, Anada T, Imaizumi H and Suzuki O: Evaluation of osteoclastic resorption activity using calcium phosphate coating combined with labeled polyanion. Anal Biochem. 410:7–12. 2011. View Article : Google Scholar
32	Hamamura K, Swarnkar G, Tanjung N, Cho E, Li J, Na S and Yokota H: RhoA-mediated signaling in mechanotransduction of osteoblasts. Connect Tissue Res. 53:398–406. 2012. View Article : Google Scholar : PubMed/NCBI
33	Wei W, Clockaerts S, Bastiaansen-Jenniskens YM, Gierman LM, Botter SM, Bierma-Zeinstra SM, Weinans H, Verhaar JA, Kloppenburg M, Zuurmond AM, et al: Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice. Osteoarthritis Cartilage. 22:293–301. 2014. View Article : Google Scholar
34	Dalby KN, Tekedereli I, Lopez-Berestein G and Ozpolat B: Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 6:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
35	Clezardin P and Teti A: Bone metastasis: Pathogenesis and therapeutic implications. Clin Exp Metastasis. 24:599–608. 2007. View Article : Google Scholar : PubMed/NCBI
36	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
37	Bieging KT, Mello SS and Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
38	Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, et al: Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 73:539–549. 2014. View Article : Google Scholar : PubMed/NCBI